BioCentury | Dec 30, 2018
Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

...mixed results (see "Hong Kong's First Wave" ). Paul Bonanos elamipretide ophthalmic solution 1% (MTP-131, bendavia, ocuvia, ss-31) IV elamipretide...
BioCentury | Jul 13, 2017
Clinical News

Stealth reports Phase II extension trial data of elamipretide in mitochondrial myopathy

...previously completed the Phase II MMPOWER trial in 36 patients with mitochondrial myopathy. In MMPOWER, IV elamipretide...
BioCentury | Oct 10, 2016
Clinical News

IV elamipretide: Phase II data

...patients ages 60-85 with documented mitochondrial dysfunction showed that a single infusion of 0.25 mg/kg/hour IV elamipretide...
...Heart Failure Society of America meeting in Orlando. Stealth BioTherapeutics Inc. , Newton, Mass. Product: IV elamipretide...
BioCentury | Jun 27, 2016
Clinical News

IV elamipretide: Phase II data

...mitochondrial myopathy associated with genetically confirmed mitochondrial disease showed that the 0.25 mg/kg/hour dose of IV elamipretide...
...to start the MMPOWER-2 extension study of MMPOWER. Stealth BioTherapeutics Inc. , Newton, Mass. Product: IV elamipretide...
Items per page:
1 - 4 of 4